Every Form 4 that Nukkleus Inc. (NUKK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUKK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUKK filings page.
T3 Defense Inc. director and Chief Executive Officer Shalom Menachem restructured his holdings through a note-for-equity exchange and an option exercise. On April 27, 2026, he entered a Note Exchange Agreement under which $2,138,962 in aggregate outstanding principal and accrued interest on promissory notes was cancelled in exchange for 4,174,399 shares of Common Stock at an exchange price of $0.5124 per share, equal to the last consolidated bid price on that date. The notes were originally acquired in connection with T3 Defense’s acquisition of Star 26 Capital, Inc. on January 12, 2026. Separately on April 27, 2026, Menachem acquired 67,009 shares of Common Stock and 2,357,303 stock purchase warrants upon exercising an option granted to him by Esousa Group Holdings LLC.
Nukkleus Inc. CEO and director Shalom Menachem, who is also a 10% owner, exercised warrants to buy more company stock. On January 29, 2026, he exercised 200,000 Common Stock Purchase Warrants at $1.50 per share for cash, receiving 200,000 restricted common shares.
After the transaction, he beneficially owned 3,442,010 shares of Nukkleus common stock directly and 4,818,359 derivative securities (warrants). This filing shows an increase in his direct equity stake through a cash exercise rather than a sale.
Nukkleus Inc. insider Shalom Menachem, who is a director, CEO and more than 10% owner, reported new equity holdings tied to the acquisition of Star 26 Capital, Inc. On January 16, 2026, he acquired 1,992,010 shares of common stock at a reported price of $0, bringing his direct common stock holdings to 3,242,010 shares. On January 15, 2026, he also received 5,018,359 common stock purchase warrants at a reported price of $0. In addition, on January 13, 2026, he acquired a call option covering 1,752,593 derivative securities, giving him the right, under a call option agreement with Esousa Group Holdings LLC, to purchase 498,003 shares of common stock and warrants to purchase 1,254,590 shares of common stock at an exercise price of $1.50 per share once Esousa has sold securities for gross proceeds of $3,000,000.
Nukkleus Inc. insider Anastasiia Kotaieva reported a series of open-market sales of the company’s common stock. On 12/22/2025, 30,000 shares were sold at a weighted average price of $4.4146 per share. On 12/23/2025, 70,000 shares were sold at a weighted average of $4.5726 per share. On 12/24/2025 and 12/26/2025, 55,604 shares were sold on each date at weighted average prices of $4.4894 and $4.2629, respectively.
After these transactions, Kotaieva beneficially owned 1,149,989 Nukkleus shares, held indirectly through X Group Fund of Funds Limited Partnership, which she owns. The filing notes she is a former director and 10% shareholder, and that each reported price reflects multiple trades within a disclosed price range.
Nukkleus Inc. (NUKK) reported an insider equity award on Form 4. A company director received 5,000 shares of common stock on 11/13/2025. The shares, with a stated price of $0 per share, were issued under the company’s 2025 Equity Incentive Plan as consideration for services rendered to Nukkleus Inc.
Following this grant, the reporting person beneficially owns 15,000 shares of Nukkleus common stock in direct ownership. The filing is made by a single reporting person in their capacity as a director of the company.
Nukkleus Inc. (NUKK) reported that a company director acquired additional common stock through an equity award. On 11/13/2025, the reporting person received 10,000 shares of Nukkleus common stock at a price of $0 per share under the company’s 2025 Equity Incentive Plan in consideration of services rendered to the company. After this transaction, the director beneficially owns 20,000 shares of Nukkleus common stock held directly.
Nukkleus Inc. (NUKK) reported an insider equity grant on a Form 4. A director received 5,000 shares of common stock on 11/13/2025 under the company’s 2025 Equity Incentive Plan as consideration for services to the company. The transaction was recorded at a price of $0.00 per share, reflecting a stock award rather than an open-market purchase. Following this grant, the director now beneficially owns 15,000 shares of Nukkleus common stock in direct ownership.
Nukkleus Inc. (NUKK) reported a director equity award on a Form 4. On 11/13/2025, the reporting person, serving as a director, acquired 5,000 shares of common stock at a price of $0. The filing explains that these shares were issued under the company's 2025 Equity Incentive Plan in consideration for services provided to the company. Following this transaction, the reporting person beneficially owned 15,000 shares of Nukkleus common stock, held directly.
Nukkleus Inc. (NUKK) reported an insider equity award to its Chief Executive Officer and director, Menachem Shalom. On 11/13/2025, he acquired 750,000 shares of Nukkleus common stock at a stated price of $0.00 per share. After this grant, he beneficially owns 1,250,000 shares of common stock in direct ownership. The filing explains that these shares were issued under the company’s 2025 Equity Incentive Plan as consideration for services rendered to Nukkleus.
Nukkleus Inc. (NUKK) insider update: Director and 10% owner Anastasiia Kotaieva reported a gift of 377,432 shares of common stock on 10/24/2025. The transaction price was $0 and is recorded as an indirect holding change via X Group Fund of Funds Limited Partnership. Following the gift, she beneficially owns 1,469,941 shares indirectly. The filing notes the transfer was a gift and states that Ms. Kotaieva is the owner of X Group Family of Funds Limited Partnership.